Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort study
Thomas Chalopin(Centre Hospitalier Universitaire de Tours), Hélène Demarquette(Ikerbasque), Jill Corre(Institut universitaire du cancer de Toulouse Oncopole), Titouan Cazaubiel(Université de Bordeaux), Murielle Roussel(Centre Hospitalier Universitaire de Limoges), Xavier Leleu(Inserm), Cécile Sonntag(Institut de Cancérologie Strasbourg), Arthur Bobin(Université de Poitiers), V. Salle(Centre Hospitalier Universitaire Amiens-Picardie), Gaëlle Labouré, Laure Vincent(Centre Hospitalier Universitaire de Montpellier), Zoé Van de Wyngaert(Centre Hospitalier Universitaire de Lille), Anne Rumpler(Centre Hospitalier Universitaire de Besançon), Elise Cellerin(Centre Hospitalier Universitaire de Tours), Andréa Pieragostini(CHU Dijon Bourgogne), Anaïs Schavgoulidze(Inserm), Véronique Morel(Sorbonne Université)
Cited by 2
Related Papers
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
|Journal of Clinical Oncology|2015|564
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
|New England Journal of Medicine|2023|538